Exelixis Inc Non Peo Neo Avg Total Comp Amt
Exelixis Inc (EXEL) reported Non Peo Neo Avg Total Comp Amt of $9.09 million for the 12-month period ending 2026-01-02, per its DEF 14A filed 2026-04-15.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-15
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2026-01-02 | $9.09M DEF 14A · filed 2026-04-15 |
| 2025-01-03 | $4.12M DEF 14A · filed 2026-04-15 |
| 2023-12-29 | $5.51M DEF 14A · filed 2026-04-15 |
| 2022-12-30 | $5.15M DEF 14A · filed 2026-04-15 |
| 2021-12-31 | $3.51M DEF 14A · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |